Skip to content

Clinical trials

Phase 2 Lymphoma, B-Cell trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lymphoma, B-Cell Phase: Phase 2 Clear all

181 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20023
20035
20045
20059
20066
20076
20085
20096
20107
20115
20122
20135
20142
20156
20165
20179
201813
20198
20206
202113
20229
202313
202411
202511
20269

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed69
Terminated30
Recruiting23
Active, not recruiting22
Unknown status21
Not yet recruiting9
Withdrawn7

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center11
Fred Hutchinson Cancer Center4
Lymphoma Study Association4
National Cancer Institute (NCI)4
Pharmacyclics LLC.4
Seagen Inc.4
Eli Lilly and Company3
International Extranodal Lymphoma Study Group (IELSG)3
Massachusetts General Hospital3
Medical College of Wisconsin3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lymphoma, B-Cell181
Lymphoma, Large B-Cell, Diffuse53
Lymphoma, Non-Hodgkin47
Lymphoma37
Lymphoma, Follicular30
Recurrence25
Lymphoma, Mantle-Cell21
Leukemia, Lymphocytic, Chronic, B-Cell20
Burkitt Lymphoma19
Lymphoma, B-Cell, Marginal Zone19

Trials

Showing 1 to 25 of 181. Each trial links to its page on Pharma Observatory.

81 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.